Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01331941
First received: March 24, 2011
Last updated: February 6, 2014
Last verified: February 2014

March 24, 2011
February 6, 2014
September 2011
February 2013   (final data collection date for primary outcome measure)
  • Area under the serum concentration-time curve (AUC) [ Time Frame: Week 1-5. ] [ Designated as safety issue: No ]
  • Maximum observed concentration (Cmax) [ Time Frame: Week 1-5. ] [ Designated as safety issue: No ]
  • Time to maximum concentration (tmax) [ Time Frame: Week 1-5. ] [ Designated as safety issue: No ]
  • Minimum observed concentration (Cmin) [ Time Frame: Week 1-5. ] [ Designated as safety issue: No ]
  • Clearance (CL) of AMG 386 calculated as dose divided by AUC on week 5. [ Time Frame: Week 1-5 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01331941 on ClinicalTrials.gov Archive Site
  • Adverse events as a measure of safety [ Time Frame: Weekly at each visit AMG 386 is administered, on day 30, 31 and 32 when only PK assessments are scheduled up to and including the last study visit 30 days after the last AMG 386 administration. ] [ Designated as safety issue: Yes ]
  • Changes in vital signs as a measure of safety [ Time Frame: Weekly at each visit AMG 386 is administered up to and including the last study visit 30 days after the last AMG 386 administration. ] [ Designated as safety issue: Yes ]
  • Changes in clinical laboratory tests as a measure of safety [ Time Frame: Weekly from week 1-9 then every 4 weeks thereafter including the last study visit 30 days after the last AMG 386 administration. ] [ Designated as safety issue: Yes ]
  • Anti-AMG 386 antibody formation [ Time Frame: Week 1, week 5, week 9 and every 16 weeks thereafter including the last study visit 30 days after the last AMG 386 administration. ] [ Designated as safety issue: Yes ]
  • Tumor objective response measured by CT or MRI (without Gadolinium contrast agents) and assessed by RECIST 1.1 criteria. [ Time Frame: Week 5 and every 8 weeks thereafter until the subject's end of participation in the study. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function

This is a phase 1, open-label pharmacokinetic study where up to 40 subjects with advanced solid tumors (up to 6-10 with normal renal function and up to 18-30 with varying degrees of renal dysfunction) will receive weekly doses of AMG 386 intravenously. The primary objective is to evaluate the pharmacokinetics (PK) of single agent AMG 386 in subjects with various degrees of renal function. Once the AMG 386 PK characterization is complete in the first 5 weeks of the study, all subjects will be allowed to continue to receive AMG 386 weekly only or subjects in group 1, 2 or 3 can opt to receive AMG 386 weekly in combination with paclitaxel until disease progression, unacceptable toxicity or withdrawal of consent.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Advanced Solid Tumors
  • Kidney Disease
  • Renal Impairment
  • Drug: AMG 386 + Paclitaxel
    15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
  • Drug: AMG 386
    15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
  • Experimental: Group 1
    Cancer subjects with normal renal function.
    Interventions:
    • Drug: AMG 386 + Paclitaxel
    • Drug: AMG 386
  • Experimental: Group 3
    Cancer subjects with moderate renal impairment.
    Interventions:
    • Drug: AMG 386 + Paclitaxel
    • Drug: AMG 386
  • Experimental: Group 4
    Cancer subjects with severe renal impairment.
    Intervention: Drug: AMG 386
  • Experimental: Group 2
    Cancer subjects with mild renal impairment.
    Interventions:
    • Drug: AMG 386 + Paclitaxel
    • Drug: AMG 386
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
November 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men or women ≥ 18 years of age
  • Must have a pathologically documented, and definitively diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy
  • Evaluable OR measurable disease by RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Life expectancy of > 3 months, in the opinion of and as documented by the investigator
  • Subject or subject's legally acceptable representative has provided informed consent

Exclusion Criteria:

  • Subjects with gastric cancer or any malignancy with purely squamous cell histology
  • Known history of primary central nervous system (CNS) tumors or CNS metastases
  • Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association > class II, uncontrolled hypertension [diastolic > 90 mmHg; systolic > 150 mmHg in repeated measurements])
  • History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1
  • Active grade 2 or greater peripheral vascular disease or peripheral edema
  • History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)
  • Non-healing wound, ulcer (including gastrointestinal) or fracture
  • Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection
  • Major surgery within 4 weeks before study day 1
  • Absolute neutrophils count (ANC) < 1.0 x 10^9/L; or platelet count < 100 x 10^9/L; or hemoglobin < 9 g/dL; or PTT / aPTT > 1.5 x institutional upper limit of normal (ULN) ); or INR > 1.5
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN (> 5.0 x ULN if liver metastases present)
  • Alkaline phosphatase > 2.5 x ULN (> 5.0 x ULN if attributable to liver or bone metastasis)
  • Total bilirubin > 1.5 x ULN
  • Other investigational procedures during the study
  • Previous anti-cancer therapy or investigational agent within 4 weeks prior to study day 1
  • Anticoagulation therapy within 4 weeks of study day 1 and while on study (except low dose warfarin (≤ 2 mg/kg) for prophylaxis against central venous catheter thrombosis)
  • Men and women of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386. Highly effective methods of birth control include sexual abstinence (men, women); vasectomy or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women).
  • Women who are lactating/breastfeeding.
  • Women with a positive pregnancy test.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01331941
20090277
Not Provided
Amgen
Amgen
Not Provided
Study Director: MD Amgen
Amgen
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP